Phase I study of Aurora a kinase inhibitor MLN8237 in advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations

Clinical Cancer Research

Volumn 18, Issue 17, 2012, Pages 4775-4784

  Dees, E Claire ^a   Cohen, Roger B ^b   Von Mehren, Margaret ^c   Stinchcombe, Thomas E ^a   Liu, Hua ^d   Venkatakrishnan, Karthik ^d   Manfredi, Mark ^d   Fingert, Howard ^d   Burris III, Howard A ^e   Infante, Jeffrey R ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; AURORA A KINASE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANUS CARCINOMA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BREAST CANCER; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; COLORECTAL CANCER; CONFUSION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENTERIC COATED TABLET; ENZYME ACTIVITY; ENZYME INHIBITION; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FIRST IN HUMAN STUDY; GALLBLADDER CARCINOMA; HEAD AND NECK CANCER; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FAILURE; HUMAN; HUMAN TISSUE; INTESTINE CANCER; LIVER CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEMORY DISORDER; MESOTHELIOMA; MITOSIS INDEX; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CARCINOMA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; SKIN BIOPSY; SKIN CANCER; SKIN EPITHELIUM; SOFT TISSUE SARCOMA; SOLID TUMOR; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AZEPINES; BIOLOGICAL AVAILABILITY; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; NEOPLASMS; NEUTROPENIA; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES;

EID: 84865741266     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0589     Document Type: Article

References (39)

1. Katayama H, Sen S. Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta 2010;1799:829-39.
2. Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci 2007;120:2987-96.
3. Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 2003;9:1420-6.
4. Mazumdar A, Henderson YC, El-Naggar AK, Sen S, Clayman GL. Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck 2009;31:625-34.
5. Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, et al. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 2008;100:1401-11.
6. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002;94:1320-9.
7. Zhang XH, Rao M, Loprieato JA, Hong JA, Zhao M, Chen GZ, et al. Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther 2008;7:1388-97.
8. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-65.
9. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22: 451-64.
10. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-93.
11. Huang XF, Luo SK, Xu J, Li J, Xu DR, Wang LH, et al. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 2008;111:2854-65.
12. Ikezoe T, Yang J, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 2007;6:1851-7.
13. Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T, et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 2009;113:66-74.
14. Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E, et al. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003;278:51786-95.
15. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003;114:585-98.
16. Glover DM, Leibowitz MH, McLean DA, Parry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995;81:95-105.
17. Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, et al. MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 2007;27:4513-25.
18. Kaestner P, Stolz A, Bastians H. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther 2009;8:2046-56.
19. KatayamaH, Zhou H, Li Q, Tatsuka M, Sen S. Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and protein phosphatase 1 through mitotic cell division cycle. J Biol Chem 2001;276: 46219-24.
20. Sasai K, Parant JM, Brandt ME, Carter J, Adams HP, Stass SA, et al. Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality. Oncogene 2008;27:4122-7.
21. Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010;115: 5202-13.
22. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, et al. Characterization of alisertib (MLN8237), an investigational small-molecule inhibitor of Aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 2011;17:7614-24.
23. Sloane DA, Trikic MZ, Chu ML, Lamers MB, Mason CS, Mueller I, et al. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. ACS Chem Biol 2010;5:563-76.
24. Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von MM, et al. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;67:945-54.
25. Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, et al. Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Cancer Res 2011;71:675-85.
26. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the pediatric preclinical testing program (PPTP). Pediatr Blood Cancer 2010;55: 26-34.
27. Tomita M, Mori N. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro. Cancer Sci 2010;101:1204-11.
28. Zhang M, Huck J, Shi J, LeRoy P, Hyer M, Sells T, et al. In-vivo characterization of the Aurora A kinase inhibitor MLN8237 in subcutaneous and disseminated models of human cancer [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. Abstract nr 5646.
29. National Cancer Institute. Common terminology criteria for adverse events version 3.0 (NCI-CTCAE). [cited 2006 Aug 9]. Available from: http://ctep cancer gov/protocoldevelopment/electronic-applications/docs/ctcaev3 pdf.
30. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-24.
31. Rojo F, Tabernero J, Albanell J, Van CE, Ohtsu A, Doi T, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006; 24:4309-16.
32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
33. Macarulla T, Cervantes A, Elez E, Rodriguez-Braun E, Baselga J, Rosello S, et al. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 2010;9:2844-52.
34. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008;14:7167-72.
35. Macarulla T, Ramos FJ, Tabernero J. Aurora kinase family: a new target for anticancer drug. Recent Pat Anticancer Drug Discov 2008;3: 114-22.
36. Chakravarty A, Yu L, Huck J, Zhang M, Burke K, Galvin K, et al. Pharmacodynamic/ pharmacokinetic/efficacy relationships of MLN8237, a small-molecule inhibitor of Aurora A kinase [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. Abstract nr 4770
37. Sharma S, Kurzrock R, Gouw L, Hong S, Jones K, Zhou X, et al. Phase I dose-escalation study of the investigational Aurora A kinase inhibitor MLN8237 as an enteric-coated tablet formulation in patients with nonhematologic malignancies. J Clin Oncol 29: 2011 (Suppl; abstr 3094).
38. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 2007;104: 4106-11.
39. Cervantes-Ruiperez A, Burris HA III, Cohen RB, Dees EC, Infante JR, Fingert H, et al. Pharmacokinetic and pharmacodynamic results from two phase I studies of the investigational selective Aurora A kinase inhibitor MLN8237: Exposure-dependent AAK inhibition in human tumors. J Clin Oncol 28: 2010 (Suppl 15; Abstr 3031).